Form 4: Supernus Exec's Stock Vesting & Tax Withholding

Supernus Pharmaceuticals' Sr. VP of IP, CSO, Padmanabh P. Bhatt, reported the vesting of 1,250 restricted stock units and the subsequent sale of 650 shares for tax obligations.

Summary

• Padmanabh P. Bhatt, Sr. VP of IP, CSO of Supernus Pharmaceuticals, Inc. (SUPN), reported changes in beneficial ownership.
• 1,250 restricted stock units (RSUs) vested on February 25, 2026, converting into 1,250 shares of Supernus common stock.
• Concurrently, 650 shares of common stock were withheld by the company to cover tax withholding requirements.
• The shares withheld for tax purposes were valued at $50.69 per share.
• Following these transactions, Bhatt beneficially owns 17,044 shares of common stock directly.
• An additional 1,250 restricted stock units remain beneficially owned as derivative securities.
• The RSU vesting occurs in four equal annual installments, with the first installment beginning on February 23, 2024.

Sentiment

Score: 6

Explanation: StockSavvy.ai views this as a neutral event, reflecting a standard executive compensation process rather than a discretionary sale or purchase indicating a change in sentiment about the company's prospects.

Positives

• Vesting of 1,250 restricted stock units indicates a portion of the executive's long-term incentive compensation has materialized.
• The executive's continued beneficial ownership of 17,044 common shares and 1,250 RSUs demonstrates ongoing alignment with shareholder interests.

Negatives

• The disposition of 650 shares, while for tax purposes, reduces the executive's direct common stock holding by that amount.

Future Outlook

Future vesting of remaining restricted stock units will occur in equal annual installments.

Industry Context

StockSavvy.ai notes that RSU vesting and subsequent tax-related sales are standard practices for executive compensation, aligning executive incentives with long-term company performance. This is a routine insider transaction.

Comparison to Industry Standards

• RSU vesting and tax withholding are standard compensation practices across industries, particularly in the pharmaceutical sector, to retain and incentivize key executives. No specific comparable companies or projects are mentioned in this filing.

Stakeholder Impact

• Shareholders: No direct impact beyond the routine nature of executive compensation and tax-related share disposition.
• Employees: No direct impact beyond the reporting person.

Next Steps

• Future annual installments of restricted stock units are scheduled to vest.

Key Dates

Recommendation

This Form 4 filing details a routine vesting of restricted stock units and a subsequent tax-related sale by a senior executive. Such transactions are standard components of executive compensation and do not typically signal a change in the company's fundamental outlook or warrant a change in investment recommendation. The executive retains a significant beneficial ownership, indicating continued alignment with shareholder interests.

Keywords

Supernus Pharmaceuticals, SUPN, Form 4, insider transaction, stock vesting, restricted stock units, RSU, executive compensation, tax withholding, beneficial ownership